241 related articles for article (PubMed ID: 9570426)
41. Amlodipine versus diltiazem CR in the reduction of the total ischemic burden: the Circadian Anti-Ischemia Program in Europe (CAPE) II trial--clinical rationale and methodology.
Deanfield JE
Cardiovasc Drugs Ther; 1998 Oct; 12 Suppl 3():239-42. PubMed ID: 9800053
[TBL] [Abstract][Full Text] [Related]
42. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
[TBL] [Abstract][Full Text] [Related]
43. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
Noll G; Lüscher TF
Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
[TBL] [Abstract][Full Text] [Related]
44. Diversity of calcium antagonists.
Pitt B
Clin Ther; 1997; 19 Suppl A():3-17. PubMed ID: 9385501
[TBL] [Abstract][Full Text] [Related]
45. [Evaluation of amlodipine in stable effort angina. Comparison with diltiazem in terms of efficacy, tolerability and maintenance of the anti-ischemic action 24 hours after the last dose].
Marchand X; Tibi T; Bernaud C; Morand P
Ann Cardiol Angeiol (Paris); 1996 Feb; 45(2):74-82. PubMed ID: 8734139
[TBL] [Abstract][Full Text] [Related]
46. Felodipine and amlodipine in stable angina pectoris: results of a randomized double-blind crossover trial.
Koenig W; Höher M
J Cardiovasc Pharmacol; 1997 Apr; 29(4):520-4. PubMed ID: 9156363
[TBL] [Abstract][Full Text] [Related]
47. A comparative study of once-daily amlodipine versus twice-daily diltiazem controlled release (CR) in the treatment of stable angina pectoris. Amlodipine Study Group.
van Kesteren HA; Withagen AJ
Cardiovasc Drugs Ther; 1998 Oct; 12 Suppl 3():233-7. PubMed ID: 9800052
[TBL] [Abstract][Full Text] [Related]
48. [Effects of long-acting calcium antagonists--amlodipine and diltiazem in patients with stable angina of effort: comparative randomized controlled trial].
Martsevich SIu; Sementsov DP; Kutishenko NP; Alimova EV
Ter Arkh; 2001; 73(9):42-6. PubMed ID: 11642080
[TBL] [Abstract][Full Text] [Related]
49. A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension.
Woittiez AJ; Huysmans FT; Bailey R; Robson RA; Mion Júnior D; Villa G; Kobrin I
Clin Nephrol; 1998 Mar; 49(3):160-6. PubMed ID: 9543597
[TBL] [Abstract][Full Text] [Related]
50. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
Bernink PJ; Prager G; Schelling A; Kobrin I
Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics and pharmacodynamics of mibefradil in hypertensive patients with varying degrees of renal insufficiency.
Welker HA; Weidekamm E; Houwing N; de Chatel R
Pharmacology; 1998 Jun; 56(6):297-307. PubMed ID: 9654216
[TBL] [Abstract][Full Text] [Related]
52. A comparison of the effects of mibefradil and atenolol on regression of left ventricular hypertrophy in hypertensive patients.
Höglund C; Cifkova R; Mimran A; Tenczer J; Watt A; Wilkins MR; Lindberg E
Cardiology; 1998 May; 89(4):263-70. PubMed ID: 9643273
[TBL] [Abstract][Full Text] [Related]
53. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
Heitmann J; Grote L; Knaack L; Köhler U; Hinder M; Peter JH
Eur J Clin Pharmacol; 1998; 54(9-10):691-6. PubMed ID: 9923569
[TBL] [Abstract][Full Text] [Related]
54. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
[TBL] [Abstract][Full Text] [Related]
55. The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension.
Lacourcière Y; Poirier L; Lefebvre J; Archambault F; Dalle Ave S; Ward C; Lindberg E
Am J Hypertens; 1997 Feb; 10(2):189-96. PubMed ID: 9037327
[TBL] [Abstract][Full Text] [Related]
56. Antianginal response to once-daily diltiazem CD in patients receiving concomitant beta-blockers, long-acting nitrates, or both. Diltiazem CD Study Group.
Heller GV; Sridharan M; Morse J; Glasser S; Beach CL
Pharmacotherapy; 1997; 17(4):760-6. PubMed ID: 9250554
[TBL] [Abstract][Full Text] [Related]
57. The effect of mibefradil on ischemic episodes with and without increase in heart rate.
Tzivoni D; Gilula Z; Klutstein MW; Reisin L; Botvin S; Kobrin I
Cardiovasc Drugs Ther; 2000 Oct; 14(5):503-9. PubMed ID: 11101198
[TBL] [Abstract][Full Text] [Related]
58. Effects of the calcium channel antagonist mibefradil on haemodynamic and morphological parameters in myocardial infarction-induced cardiac failure in rats.
Sandmann S; Spitznagel H; Chung O; Xia QG; Illner S; Jänichen G; Rossius B; Daemen MJ; Unger T
Cardiovasc Res; 1998 Aug; 39(2):339-50. PubMed ID: 9798519
[TBL] [Abstract][Full Text] [Related]
59. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
[TBL] [Abstract][Full Text] [Related]
60. Amlodipine versus diltiazem as additional antianginal treatment to atenolol. Centralised European Studies in Angina Research (CESAR) Investigators.
Knight CJ; Fox KM
Am J Cardiol; 1998 Jan; 81(2):133-6. PubMed ID: 9591893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
